On March 20, 2024, a confirmation letter reached the editorial office of Translational Breast Cancer Research (TBCR) that the journal met the selection criteria necessary to be included in the Emerging Sources Citation Index. Articles published in TBCR since 2020, beginning with Vol 1, will be included in Emerging Sources Citation Index.
The Emerging Sources Citation Index (ESCI) is a citation index produced since 2015 by Thomson Reuters and now by Clarivate. According to the publisher, the index includes "peer-reviewed publications of regional importance and in emerging scientific fields" (1). Journals in ESCI have passed an initial editorial evaluation and can continue to be considered for inclusion in products such as SCIE, SSCI, and AHCI (1). All ESCI journals are indexed according to the same data standards, including cover-to-cover indexing, cited reference indexing, subject category assignment, and indexing all authors and addresses (1).
Translational Breast Cancer Research (Transl Breast Cancer Res, TBCR, Online ISSN 2218-6778) launched in November 2019, is an open-access, peer-reviewed journal focusing on translational research in breast cancer. As a quarterly published journal, the journal seeks to create a platform for researchers and clinicians by presenting pertinent investigations, discussing critical questions relevant to the entire field of breast cancer, and aiming to develop new perspectives for all those issues concerned with breast cancer. As one of the most serious problems of oncology and the leading cause of death of women in many countries, breast cancer is truly a multidisciplinary problem to be handled. Each issue will contain articles dealing with laboratory investigations as well as articles dealing with clinical studies. (Figure 1)
Figure 1 The confirmation letter
With great efforts from the Editor-in-Chief, editorial board members, authors, reviewers, and the entire editorial team, TBCR has published 134 articles as of December 31st, 2023, including 19 Original Articles, 40 Review Articles, and 14 Case Reports. We herein would like to extend our sincere gratitude to all the contributors. We will continue striving to publish high-quality articles and bring TBCR to the forefront.
Reference
1. "ESCI Fact Sheet" (PDF). Clarivate.
Editorial Office
Translational Breast Cancer Research